TY - JOUR
T1 - B Cell Activation Results in IKK-Dependent, but Not c-Rel- or RelA-Dependent, Decreases in Transcription of the B Cell Tolerance-Inducing Gene Ets1
AU - Kearly, Alyssa
AU - Ottens, Kristina
AU - Battaglia, Michael C.
AU - Satterthwaite, Anne B.
AU - Garrett-Sinha, Lee Ann
N1 - Funding Information:
Received for publication October 31, 2022. Accepted for publication October 31, 2022. Address correspondence and reprint requests to: Dr. Lee Ann Garrett-Sinha, Department of Biochemistry, State University of New York, Jacobs School of Medicine and Biomedical Sciences, 955 Main Street, Room 5124, Buffalo, NY 14203. E-mail address: leesinha@buffalo.edu ORCID: 0000-0001-7806-4352 (L.A.G.-S.). This work was supported by grants from the Lupus Research Alliance and the National Institute of Allergy and Infectious Diseases (Grant R01 AI122720) as well as by National Cancer Institute Core Center Grant P30CA016056 to the Roswell Park Cancer Institute. A.B.S. is a Southwestern Medical Foundation Scholar in Biomedical Research and holds the Peggy Chavellier Professorship in Arthritis Research and Treatment. Abbreviations used in this article: CHX, cycloheximide; KO, knockout; Pol II, polymerase II; qPCR, quantitative PCR. The online version of this article contains supplemental material. This article is distributed under the terms of the CC BY-NC 4.0 Unported license.
Funding Information:
This work was supported by grants from the Lupus Research Alliance and the National Institute of Allergy and Infectious Diseases (Grant R01 AI122720) as well as by National Cancer Institute Core Center Grant P30CA016056 to the Roswell Park Cancer Institute. A.B.S. is a Southwestern Medical Foundation Scholar in Biomedical Research and holds the Peggy Chavellier Professorship in Arthritis Research and Treatment. We thank Kirsten Smalley for technical assistance and Dr. Satrajit Sinha for helpful discussions.
Publisher Copyright:
© 2022 The Authors.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Ets1 is a key transcription factor in B cells that is required to prevent premature differentiation into Ab-secreting cells. Previously, we showed that BCR and TLR signaling downregulate Ets1 levels and that the kinases PI3K, Btk, IKK, and JNK are required for this process. PI3K is important in activating Btk by generating the membrane lipid phosphatidylinositol (3,4,5)-trisphosphate, to which Btk binds via its PH domain. Btk in turn is important in activating the IKK kinase pathway, which it does by activating phospholipase Cg2fiprotein kinase Cb signaling. In this study, we have further investigated the pathways regulating Ets1 in mouse B cells. Although IKK is well known for its role in activating the canonical NF-kB pathway, IKK-mediated downregulation of Ets1 does not require either RelA or c-Rel. We also examined the potential roles of two other IKK targets that are not part of the NF-kB signaling pathway, Foxo3a and mTORC2, in regulating Ets1. We find that loss of Foxo3a or inhibition of mTORC2 does not block BCR-induced Ets1 downregulation. Therefore, these two pathways are not key IKK targets, implicating other as yet undefined IKK targets to play a role in this process.
AB - Ets1 is a key transcription factor in B cells that is required to prevent premature differentiation into Ab-secreting cells. Previously, we showed that BCR and TLR signaling downregulate Ets1 levels and that the kinases PI3K, Btk, IKK, and JNK are required for this process. PI3K is important in activating Btk by generating the membrane lipid phosphatidylinositol (3,4,5)-trisphosphate, to which Btk binds via its PH domain. Btk in turn is important in activating the IKK kinase pathway, which it does by activating phospholipase Cg2fiprotein kinase Cb signaling. In this study, we have further investigated the pathways regulating Ets1 in mouse B cells. Although IKK is well known for its role in activating the canonical NF-kB pathway, IKK-mediated downregulation of Ets1 does not require either RelA or c-Rel. We also examined the potential roles of two other IKK targets that are not part of the NF-kB signaling pathway, Foxo3a and mTORC2, in regulating Ets1. We find that loss of Foxo3a or inhibition of mTORC2 does not block BCR-induced Ets1 downregulation. Therefore, these two pathways are not key IKK targets, implicating other as yet undefined IKK targets to play a role in this process.
UR - http://www.scopus.com/inward/record.url?scp=85143088528&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143088528&partnerID=8YFLogxK
U2 - 10.4049/immunohorizons.2100065
DO - 10.4049/immunohorizons.2100065
M3 - Article
C2 - 36445360
AN - SCOPUS:85143088528
SN - 2573-7732
VL - 6
SP - 779
EP - 789
JO - ImmunoHorizons
JF - ImmunoHorizons
IS - 11
ER -